US-China Biopharma Congress **2019**
SAPA-GP 17th Annual Conference

Innovate and Collaborate

Thriving in the Changing Dynamics of Global Life Sciences

May 31, 2019
Sheraton Valley Forge Hotel
480 N Gulph Rd, King of Prussia, PA 19406

美中藥協 SAPA
Philadelphia 費城
www.sapa-gp.org
2019 Annual Conference

Greetings from Conference Co-Chairs

Dear SAPA-GP Members and Friends:

Welcome to the 17th Annual Conference of the Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP).

We are proud to present to you a conference that covers both the US and China and features the changing dynamics of global life sciences, immunology renaissance, transformational therapeutic modalities, business development and strategic partnerships, innovative clinical trial designs, career development, and job fair. This one-day event will provide a venue for you to interact with hundreds of executive leaders, scientists, entrepreneurs, investors, recruiters, human resource specialists, and other life science service providers.

We would like to take this opportunity to acknowledge our Senior Leadership Team and Executive Council members for delivering a series of high impact events and initiatives in 2018-2019.

Led by Dr. Haifeng Cui and Dr. Hanghang Zhang, our flagship program, Philadelphia Pharmaceutical Symposium, gathered world leaders to a day of "Immuno-Oncology 2.0". One of the highlights is the keynote speech by Dr. Carl June, who highlighted cutting edge research on fighting cancer with cell therapies. The symposium attracted more than 350 scientists from academia, biotech, and pharmaceutical companies.

Under the leadership of Dr. Yufeng Li and Dr. Yongchao Su, SAPA-GP offered the 2nd Advanced Course on Pharmaceutical R&D and a new Executive Training Course. These one-day courses were taught by experienced industrial leaders and covered disciplinary areas in the pharmaceutical value chain and major therapeutic areas.

Fostering the growth of our talented young scientists is one of SAPA-GP priorities. Led by Dr. David Cragin, SAPA-GP held a Career Development Workshop at the University of Pennsylvania in September 2018. The workshop discussed hot topics on landing the first job and pursuing a rewarding career in the life sciences industry. The workshop attracted attendees from Pennsylvania, Delaware, New York, New Jersey, and Ohio. In addition, under the leadership of Ms. Hao Sun, our individually tailored Mentorship Program continued into its third successful year with an expanded mentee/mentor pool.

We would also like to express our eternal gratitude towards our sponsors, speakers, volunteers, friends and family members of SAPA-GP. Your generosity and support makes it possible for SAPA-GP to be a valuable platform and resource for our members and corporate partners. By doing this, you are helping to ensure that Greater Philadelphia remains a vibrant and growing area for life sciences.

Together we are shaping the future of the life sciences industry and making our world healthier!

Please check out our upcoming SAPA-GP Liberty Venture Forum in partnership with RESI Conference on June 3.

Enjoy the conference!



Han Dai, Ph.D.
Conference Co-Chair
President, SAPA-GP,
Executive Director, BeiGene

Jing Yang, Ph.D.
Conference Co-Chair
President-Elect, SAPA-GP,
Lead, Pan Asian Network, People and
Business Resource Group, BMS

SAPA-GP History

The Greater Philadelphia area is one of the major homes for the world's pharmaceutical industry. It hosts more than half of the world's top-ten pharmaceutical companies, and many small/mid-size biotech companies as well as academic institutions. The Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP) was established in 2002 to serve the rapidly growing pharmaceutical/biotech/healthcare community in the GP area.

SAPA-GP Mission

To promote pharmaceutical sciences and biotechnology
To contribute to public health education by raising public awareness
To facilitate scientific and business cooperation between US and China
To foster career development of pharmaceutical professionals

2018~2019 SAPA-GP Events & Achievements

2018/06/09 2nd SAPA-GP Advanced Course on Pharmaceutical R&D and Executive Training Course with over 50 trainees received training certificates

2018/07/17 SAPA-GP Meeting with Montgomery County discussion Development Corporation

2018/07/25 Representatives from Changzhou visited Philadelphia and signed collaboration agreement with SAPA-GP

2018/08/20 SAPA-GP supported Across Golden Bridge: China-US Cultural Heritage and Urban Development Forum

2018/09/22 SAPA-GP Career Development Workshop for postdoctoral fellows and graduate students was held at University of Pennsylvania

2018/10/16 SAPA-GP participated in the Philadelphia and Yangzhou Talent Exchange Forum held at Drexel University

2018/12/08 Philadelphia Pharmaceutical Symposium "Immuno-Oncology 2.0" with Dr. Carl June as the Keynote Speaker attracted more than 350 attendees from academia, biotech, and pharmaceutical companies

2019/02/01 SAPA-GP Chinese New Year dinner at Lailai Garden

2019/02/11 2019 SAPA-GP Mentor-Mentee Program started

2019/04/16 SAPA-GP Supported Asia Pharma R&D Leaders Summit 2019 in Shanghai

2019/05/04 SAPA-GP Summer Picnic at Wilson Farm Park, PA

2019/05/31 SAPA-GP 17th Annual Conference at Sheraton Valley Forge Hotel at King of Prussia, PA

2019/06/03 SAPA-GP Liberty Bell Venture Forum RESI 2019 in Philadelphia

Conference at-a-Glance

8:00 – 8:25 AM	**Registration and Networking**	
8:25 – 8:30 AM	**Opening Speech**	**Grand Ballroom**
8:30 – 8:50 AM	**Presidential Election Speech**	**Grand Ballroom**
9:00 – 10:00 AM	**Plenary Session:** **Changing Dynamics of Global Life Science**	**Grand Ballroom**

10:15 -11:45 AM Morning Sessions I – V

Track I (Morning):	Track II (Morning):	Track III (Morning):	Track IV (Morning):	Track V (Morning):
Immunology Renaissance: the Yin and Yang of Immunomodulation and Therapeutic Innovation Grand Ballroom	Gene Therapy: Therapeutic Insights and Commercial Hurdles Centennial Ballroom III	The Evolving Landscape and Trends in Biopharma Collaboration Frazer	CEO Forum Centennial Ballroom I	Diverse in Changing Career Pathways in Life Sciences Centennial Ballroom II

12:00 PM -1:00 PM Lunch Sessions (Session VI)

Lunch Session A: Fundraising Boot Camp Strafford	**Lunch Session B:** Sudden Wealth with My Hong Kong Listed IPO Shares: What Next? Haverford

Afternoon Sessions I - V

1:15 – 2:15 PM **Track I (Afternoon):** Immunology Renaissance: The Yin and Yang of Immunomodulation and Therapeutic Innovation Grand Ballroom	**1:15 – 2:45 PM:** **Track II (Afternoon):** Expanding Horizon of Small Molecule Discovery Centennial Ballroom III	**1:15 – 2:45 PM** **Track III (Afternoon):** Business Development and Licensing: Strategic Drivers for Making the Right Deals Frazer	**1:15 – 3:00 PM** **Track IV (Afternoon):** Innovative Trial Design Centennial Ballroom II	**2:00 – 5:00 PM** **Track V (Afternoon):** Job Fair Centennial Ballroom I
	3:15 – 4:45 PM **Track II (Afternoon):** Emerging Technology Trend in Biological Development Centennial Ballroom III	**3:15 – 4:45 PM** **Track III (Afternoon):** Alliance Management in Making a Collaboration Work Frazer	**3:15 – 4:45 PM** **Track IV (Afternoon):** Healthcare Advocacy Centennial Ballroom II	



AGENDA

8:00-8:25 a.m. Registration and Networking
8:25-8:30 a.m. Opening Speech
8:30-8:50 a.m. Presidential Election Speech

Plenary Session : Changing Dynamics of Global Life Science — Grand Ballroom

Session chairs: Han Dai, Ph.D. Executive Director, BeiGene
Yufeng Li, Ph.D. Senior Director, Clinical Sciences and Translational Medicine, Transcenta

9:00-9:30 a.m. Felix Hsu, M.B.A. SVP, WuXi Advanced Therapies
Meeting the Challenge of Manufacturing Advanced Therapies: Cell Therapies, Gene-mediated Cell Therapies and Viral Vectors

9:30-10:00 a.m. Sean (Xi-Yong) Fu, Ph.D., M.B.A. President, Luye Boston R&D LLC.
Thoughts and Observations on Globalization of China Biopharm Companies

Track I Science — Grand Ballroom

Session I Immunology Renaissance: the Yin and Yang of Immunomodulation and Therapeutic Innovation

Sponsored by Simcere

Session chairs: Zhiyun Wen, Associate Principal Scientist, Merck & Co.
Chun Shao, Ph.D. Scientist II, BMS
Fang Shen, Ph.D. Associate Scientific Director, Johnson & Johnson
Xin-jun Zhang, Ph.D. Senior Scientist, Merck & Co.

10:15-10:45 a.m. Jan Joseph Melenhorst, Ph.D. Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania
The Natural Foundation of Chimeric Antigen Receptor T-cell Therapies

10:45-11:15 a.m. Jenny Xie, Ph.D. Director, Discovery Immunology, BMS
Discovery of a Potent, Selective, Allosteric Tyk2 Inhibitor BMS-986165 for the Treatment of Autoimmune Diseases

1:15-1:45 p.m. Eric Hostetler, Ph.D. Executive Director, Translational Imaging Biomarkers, Merck & Co.
Imaging Neuroinflammation: Opportunities, Challenges, and Future Directions

1:45-2:15 p.m. Dai Wang, Ph.D. Principal Scientist, Merck & Co.
In Pursuit of a Cytomegalovirus Vaccine

Track II Technology — Centennial Ballroom III

Session II Gene Therapy: Therapeutic Insights and Commercial Hurdles

Sponsored by WuXi AppTec

Session chairs: Zhenhua Wu, Ph.D. Founder & CEO, Landes Therapeutics
Yeqing Tao, Ph.D. Investigator, GSK

10:15-10:35 a.m. Zhenhua Wu, Ph.D. Founder & CEO, Landes Therapeutics
Is Cell and Gene Therapy the Hope of the Future?

10:35-10:55 a.m. J. Fraser Wright, Ph.D. Chief Technology Officer, Axovant Gene Therapies
Viral Vector CMC: Progress and Challenges for Commercialization of New Paradigm Therapeutics

10:55-11:15 a.m. Qingrui You, Ph.D. Process Director, OBiO Technology (Shanghai) Corp., Ltd.
Gene Therapy Product IND Roadmap and Market Trend in China

11:15-11:35 a.m. Aaron Weinstein, Senior Director, Validation Services, Integrated Project Services
Qualification and Validation Considerations for Cell and Gene Therapy Projects

Session III Expanding Horizon of Small Molecule Discovery

Session chairs: Jian Wu, Ph.D. Director, R&D, Progenra Inc.
Zhipeng Zheng, Ph.D. Candidate, University of Pennsylvania

1:15-1:45 p.m. Linghang Zhuang, Ph.D. Head of Chemistry, Eternity Biosciences Inc.
An Introduction to R&D of Hengrui Medicine

1:45-2:15 p.m. Tauseef R. Butt, Ph.D. President & CEO, Progenra Inc.
PROTAC Drugs: Novel Therapeutic Approach for Ubiquitin Mediated Degradation of Targets

2:15-2:45 p.m. Mike Hu, Ph.D. Chief Development Officer, Rafael Pharmaceuticals
Harness Cancer Metabolism to Develop Innovative Therapies

Session IV Emerging Technology Trends in Biological Development

Session chairs: Lu Wang, Ph.D. Associate Director, Teva Pharmaceuticals
Yongchao Su, Ph.D. Associate Principal Scientist, Merck&Co.

3:15-3:45 p.m. Jason K. Cheung, Ph.D. Executive Director, Pharmaceutical Sciences, Merck & Co.
Expanding the Characterization Toolkit to Facilitate Biologics Development

3:45-4:15 p.m. Huabin Sun, M.D. Senior Medical Director, Clinical Research & Development, Janssen Pharmaceuticals
Biological and Cell Therapy in Hematological Malignancies

4:15-4:45 p.m. Camilo Moncada, Ph.D. Director, Custom Research, Rockland Immunochemicals
Development of Antibodies to Anti-Sense-Oligonucleotides

Track III Business

Frazer

Sponsored by Luye Pharma

10:15-10:20 a.m. Opening Remarks, Objectives, and Introduction

Session V The Evolving Landscape and Trends in Biopharma Collaboration

Session chair: Dennis Gross, Ph.D. CEO, Pennsylvania Drug Discovery Institute

10:20-10:50 a.m. Cynthia Cai, Ph.D., M.B.A. Senior Advisor, Northern Light Venture Capital
Opportunities and Challenges in Driving Innovation in Today's Global Life-sciences Space

10:50-11:20 a.m. Frederick "Rick" Jones, M.D., M.B.A. Partner, BioAdvance
Collaborations in the Changing Pennsylvania Life-sciences Ecosystem

11:20-11:45 a.m. Moderated Panel Discussion and Q&A

Session VI Business Development and Licensing: Strategic Drivers for Making the Right Deals

Session chair: Shuang "Steve" Wu, Ph.D. Consulting Associate, Life Sciences Practice, Charles River Associates

1:15-1:45 p.m. Bob Ai, Ph.D., M.B.A. Managing Director, Solebury Trout
Bolstering R&D Pipelines through Acquisitions, Licensing, and Strategic Alliances

1:45-2:15 p.m. Jay (Jie) Liu, M.B.A. Managing Director, Torreya
Cross-border Collaboration between the U.S. and China

2:15-2:45 p.m. Moderated Panel Discussion and Q&A

Session VII Alliance Management in Making a Collaboration Work

Session chair: Danhui Wang, M.B.A. Founder, Remedeca Partners, LLC.

3:15-3:45 p.m. Henry (He) Sun, Ph.D. VP, Tasly Holding Group, Co. Ltd, Co-founder & CEO, Tasly Pharmaceuticals, Inc. USA
The Tasly Story - Going Global via Effective Collaborations

3:45-4:15 p.m. Nando Bansal, Ph.D., M.B.A. Sr. Director, Project and Alliance Leader, Janssen Pharma
Making Big Pharma Strategic Alliances Work

4:15-4:45 p.m. Moderated Panel Discussion and Q&A

Track IV Global Health

Session VIII CEO Forum

Centennial Ballroom I

Session chairs: Bo Liang, Ph.D., M.B.A. Co-Founder & President, IVIEW Therapeutics Inc.
Laura Hong, M.D., Ph.D. President, KLUS Pharma Inc.
Di Wu, Ph.D. Candidate, Temple University

10:15-10:30 a.m. Tom (Tao) Du, M.D., Ph.D. Medical Partner, Shenzhen Share Capital Co., Ltd.
New Challenges and Opportunities in Chinese Pharmaceutical Industry

10:30-10:45 a.m. Sue Dillon, Ph.D. Co-Founder, President & CEO, Aro Biotherapeutics
Aro Biotherapeutics: Next Generation Protein Medicines

10:45-11:00 a.m. Kevin Heyeck, Venture Partner, 6 Dimensions Capital
An Introduction to 6 Dimensions Capital & First Year Score-Card

11:00-11:15 a.m. Daniel Du, M.D., Ph.D. SVP, Hua Medicine (Shanghai), Ltd.
Innovation from Concept to Medicine: Discovery and Development of Dorzagliatin to Stop Diabetes

11:15-12:00 p.m. Panel Discussion: Entrepreneurship in Life Science Industry

Mike Chen, President, ACROBiosystems
Sean (Xi-Yong) Fu, Ph.D., M.B.A. President, Luye Boston R&D LLC.
Laura Hong, M.D., Ph.D. President, KLUS Pharma Inc.
Frank (Feng) Li, Ph.D. President, Alliance Pharma
Li Yan, M.D., Ph.D. Chief Medical Officer, Brii Biosciences
Xiaofeng Meng, Ph.D., M.B.A. CEO, Epic Pharma, CEO, PuraCap Pharmaceutical
Henry (He) Sun, Ph.D. VP, Tasly Holding Group, Co. Ltd, Co-founder & CEO, Tasly Pharmaceuticals, Inc. USA

Session IX Innovative Trial Design — Centennial Ballroom II

Session chairs: Haichen Yang, M.D. VP, Neuroscience, ICON Plc.
Li Yan, M.D., Ph.D. Chief Medical Officer, Brii Biosciences

1:15-1:45 p.m. Larry Alphs, M.D., Ph.D. Deputy Chief Medical Officer, Newron Pharmaceuticals US, LLC.
Models for Increasing Real World Evidence in Registration and Post-Approval Clinical Trials

1:45-2:15 p.m. Shell (Xiaoshuang) Li, M.D. Chief Medical Officer and Chief Operating Officer, Hengruiyuan
Clinical Studies of MASCT: Past, Present and Future

2:15-2:45 p.m. Timothy W. Victor, Ph.D. Global Head and Vice President of Biostatistics, ICON Innovation Center
Innovations in Clinical Trials Designs

2:45-3:00 p.m. Panel Discussion
Chris Hansis, M.D., Ph.D. Founder & CEO, Phase Clinical Services

Session X Healthcare Advocacy — Centennial Ballroom II

Session chairs: Li Cui, Ph.D. Investigator, GSK
Hanghang Zhang, Ph.D., M.D. Student, Associate Scientist, Temple University

3:15-3:45 p.m. Chari Cohen, Dr.P.H., M.P.H. SVP, the Hepatitis B Foundation
The Policy and Advocacy Landscape: Integrating the Patient Voice into Drug Development and Clinical Research

3:45-4:15 p.m. Anya Harry, M.D., Ph.D. Global Lead, Clinical Trial Diversity, GSK
The Importance of Demographic Diversity in Drug Development

4:15-4:45 p.m. Amy Leader, Dr.P.H., M.P.H., Associate Professor, Department of Medical Oncology, Thomas Jefferson University
Patient and Community Engagement in Cancer Prevention Research

Track V Career

Session XI Diverse in Changing Career Pathways in Life Sciences — Centennial Ballroom II

Session chairs: David Cragin, Ph.D. Global Safety & Science & Science, Merck & Co.
Hao Wu, Ph.D. Technical Specialist, Howson & Howson LLP.

10:15-10:45 a.m. Don Kraft, EVP, Strategic Initiatives, ICON Plc.
Career Pathways: Charting Your Own Course

10:45-11:15 a.m. Yuan Yu, Ph.D. EVP, Association of Bio-industry Experts, Chengdu High Tech Zone
Chengdu's High Technology Zone: A Biotech Ecosystem

11:15-11:45 a.m. Mike Hu, Ph.D. Chief Development Officer, Rafael Pharmaceuticals
A Journey of Passion

Session XII Job Fair 2:00-5:00 p.m. — Centennial Ballroom I

Session chairs: Tiger Bee, M.B.A. Clinical Study Manager, Klus Pharma
Pengbo Guo, Ph.D. Temple University

JOB FAIR

12:00 - 1:00 p.m. Networking and Lunch

Sponsored by Acro BIOSYSTEMS

Track VI 12:00 - 1:00 p.m. Lunch Session

Fundraising Boot Camp — Strafford

This workshop provides a top-to-bottom master class on outbound global fundraising.

Session chair: Xin Xin, Ph.D. Scientist, Biologics CMC, Teva Pharmaceuticals

Speaker: Dennis Ford, Founder & CEO, Life Science Nation, Creator of RESI Conference — Haverford

Sudden Wealth with My Hong Kong Listed IPO Shares: What Next?

Session chair: Yu Gao, Biological Researcher, Teva Pharmaceuticals

Speakers: Catherine Zhang, M.B.A. International Financial Advisor, Portfolio Manager, Morgan Stanley Wealth Management

Irene Liu, M.B.A. Financial Advisor, Portfolio Manager, Morgan Stanley Wealth Management

Gala Dinner: The Night of Chengdu (Invitation Only) — Grand Ballroom

Sponsored by 成都高新 CDHT

Gala host: David Cragin, Ph.D. Global Safety & Science & Science, Merck & Co.
Li Cui, Ph.D. Investigator, GSK

6:00-6:15 p.m. Demonstrate Bio-industrial Ecosphere in Chengdu High-tech Zone
Chengdu High Tech Zone

6:15-6:25 p.m. Video about Bio-industrial Ecosphere in Chengdu High-tech Zone
Chengdu High Tech Zone

6:25-6:30 p.m. Signing Ceremony

6:30-6:45 p.m. Guest Presentation
Jijun Xing, Ph.D. Science and Technology Counselor, Chinese Consulate-General in New York

6:45-6:50 p.m. Year-end Remarks
Han Dai, Ph.D. President, SAPA-GP, Executive Director, Discovery Biology, BeiGene (Beijing) Co., Ltd

6:50-6:55 p.m. SAPA-GP 2019-2020 Presidential Election Result
Jing Yang, Ph.D. President-Elect, SAPA-GP, Lead, Pan Asian Network, People and Business Resource Group, BMS

6:55-7:00 p.m. Volunteer of the Year Recognition

SPONSORS

成都高新 CDHT · Acro BIOSYSTEMS · Luye Pharma · Simcere 先声药业 · 药明康德 WuXi AppTec

Bristol-Myers Squibb · 科伦药业 KELUN PHARMACEUTICAL · PHASE CLINICAL SERVICES · ROCKLAND antibodies & assays · Alliance PHARMA

AVE · BIODURO · FRONTAGE YOUR DRUG DEVELOPMENT PARTNER · GenScript Make Research Easy · 恒瑞 Hengrui Medicine

iview THERAPEUTICS · OBiO 和元上海 · PriMera · Protheragen 普赛睿 · RESI Created & Produced by LIFE SCIENCE NATION

分享投资 SHARE CAPITAL · YOURWAY TRANSPORT TIME SENSITIVE BIOPHARMA SERVICES · AIG · BGI GLOBAL GENOMIC SERVICES · Morgan Stanley

ZHENG & KARG LLP ATTORNEYS AT LAW · BioKatalyst Inspire Biopharma Commercial Leadership

SPEAKERS

Larry Alphs, M.D., Ph.D.

Deputy Chief Medical Officer, Newron Pharmaceuticals US, LLC

Larry Alphs is Deputy Chief Medical Officer at Newron Pharmaceuticals US, LLC. He obtained his M.D. and Ph.D. from the University of Chicago Pritzker School of Medicine. Larry worked for 10 years as a researcher/clinician specializing in clinical research in persons with serious psychiatric disorders. For most of his career Larry has worked in various aspects of clinical development, with positions at Novartis, Knoll Pharmaceuticals, Pfizer, Janssen and Newron. He has done Phase I-IV work in a variety of CNS disorders, including schizophrenia, bipolar disorder, suicidality, anxiety, depression, epilepsy, neuropathic pain, and traumatic brain injury. His interests have focused on the nosology and treatment of and suicidal ideation and behavior, especially those observed in schizophrenia, and depression. He is a founder of the International Society for CNS Clinical Trials and Methodology, and now serves on its board. Larry has authored numerous peer-reviewed journal articles and book chapters and has developed proprietary scales for use in psychiatric evaluations.

Bob Ai, Ph.D., M.B.A.

Managing Director, Solebury Trout

Bob Ai is a Managing Director at Solebury Trout focusing on establishing long term relationships with biotech companies and investors in Asia. Previously, he was Managing Director, Senior Biotech Analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company. He has also served as Principal in crossover life science private equity firm Merlin Nexus and senior equity analysts at assets management firms Bennett Lawrence and Merlin Biomed Group. Bob received his PhD and MBA from Penn State University and did postdoctoral training at University of Pennsylvania. He has published eight articles in peer-reviewed scientific journals. He also won the prestigious Ray Wu scholarship for outstanding Chinese Student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.

Nando Bansal, Ph.D., M.B.A.

Senior Director, Project and Alliance Leader, Janssen Pharmaceuticals

Nando Bansal, Ph.D., MBA, is currently Senior Director, Project and Alliance Leader at Janssen, Pharmaceutical sector of Johnson & Johnson. During his 12-year tenure at JNJ he has led major strategic alliances in Immunology and product development teams. Prior to joining JNJ he served as a strategic project and alliance leader at Millennium Pharma (now Takeda) and Wyeth. Nando has more than 25 years of experience in drug development, project leadership, and alliance and integration management. Nando obtained his Ph.D. in Pharmaceutics from St. John's University, New York and MBA from Baruch College, NY. He has taken several leadership and management courses at Harvard and Wharton. Nando is currently an adjunct faculty at Jefferson University teaching graduate course in Strategic Pharma R&D management.

Tauseef R. Butt, Ph.D.

President & CEO, Progenra Inc.

Tauseef R. Butt obtained his Ph.D. degree in Molecular Biology from The University of Glasgow, Scotland. He was a Staff Fellow at the National Institutes of Health, Bethesda, MD, before joining SmithKline Beckman (now GSK) Pharmaceuticals. He was Assistant Director in Research and Development at Smith Kline. He also served as Adjunct Professor Biochemistry and Biophysics, University of Pennsylvania Medical School, Philadelphia. He has published about 100 papers in life sciences research. He has raised several million dollars capital and launched highly innovative and profitable biotechnology companies.

Cynthia Cai, Ph.D., M.B.A.

Senior Advisor, Northern Light Venture Capital

Cynthia Cai is a senior advisor for Northern Light Venture Capital, a leading venture capital firm for Healthcare, TMT, and Advanced Technologies. She is focused on early-stage investments in the US healthcare sector. Before joining Northern Light, Dr. Cai had over 20 years of experience in leadership positions with one of the world's most respected biotech companies. As senior director of marketing in the Mass Spec. Division for Agilent Technologies, she was responsible for global thought leader collaboration and solution development for its billion-dollar MS business. Before that, as a business development manager and product marketing manager, Dr. Cai was involved in multiple acquisitions and divestitures, also led a $500+ million-dollar flagship product development and its global commercialization.

Dr. Cai earned a B.A. and Master of Engineering from Tsinghua University, received her Ph.D. in Chemistry from the University of Massachusetts and her MBA from The Wharton Business School of the University of Pennsylvania. She served as Delaware governor economic advisor, a member of the Board of the Forum for Executive Women (FEW-DE). She has also been a mentor for Wharton EMBA, Tsinghua University Global MBA and Drexel LeBow School of Business for many years. Dr. Cai had been a regular speaker at healthcare conferences such as China Focus at J.P. Morgan Week, SAPA Annual Conference. She is also a regular speaker at Wharton China Business Forum, and Sino-American Pharmaceutical Professionals Association for topics related to cross-border commercialization and cross-culture career development.

Mike Chen

President, ACROBiosystems

Mike Chen works as President in ACROBiosystems. In 2011, he raised funds to establish the brand "ACROBiosystems"; meanwhile he built the company's core management team, optimized the organizational structure, and laid out the market network. Mr. Chen took the lead to establish 8 biotechnology experiment platforms with a total area of 4100 square meters, which is invested tens of millions of RMB in fixed assets. The company has a worldwide sales network. Except the headquarter in Beijing, the sales offices in Shanghai China and branches in the US serve the end customers around the world, where includes more than 2,000 top pharmaceutical companies and research institutions such as Pfizer, Novartis and Harvard Medical School. Professional teams led by him have initially developed the world's first person-derived PD-1 full-length recombinant protein, produced more than 3,000 kinds of recombinant protein products, and undertaken a number of technical service projects.

Previously, he successively worked as the supervisor of the application lab and the scientist of biological process application for Life Technologies/Thermo Fisher. At this time, he led to establish the medium product laboratory in China for Life Technologies, developed the R&D and pre-clinical production of more than 30 protein expression projects, led the development of the production process of new antibody drugs, and led the team to develop 8 kinds of serum-free culture media suitable for different cells and applications. Mr. Chen has over 15 years of abundant experience in product development, operation management, and international market development in pharmaceutical and biotechnology industries.

Jason K. Cheung, Ph.D.

Executive Director, Pharmaceutical Sciences, Merck & Co.

Jason K. Cheung has over 12 years of experience in both large and small molecule product development, having held roles of increasing responsibility in Bioprocess Development and Pharmaceutical Sciences at Merck. He was a key contributor for multiple marketed products as the drug product formulation lead for Noxafil-IV (posaconazole), Zinplava (bezlotoxumab), and Lusduna (insulin glargine). Recently, Jason has led the large molecule biologics biophysical characterization group. During his tenure in this role, he established core capabilities and filing strategies for higher order structure characterization, expanded the subvisible particle characterization tool kit, and integrated harmonized biochemical testing workflows and capabilities within the large molecule formulation development area. Currently, Jason is leading the Preformulation Department. The Mission for this group includes generating foundational knowledge through evaluating and developing advanced characterization technologies and leveraging existing tools to understand physico-chemical and biophysical drug product properties mechanistically.

Chari Cohen, Dr.P.H., M.P.H.

Senior Vice President, Hepatitis B Foundation (HBF), Pennsylvania Biotechnology Center

Chari Cohen is Senior Vice President at the Hepatitis B Foundation (HBF), located at the Pennsylvania Biotechnology Center in Doylestown, PA. For the past 18 years, she has planned, implemented and evaluated community programs and research projects focusing on hepatitis B and liver cancer. Her experience focuses on reducing hepatitis B related health disparities, improving capacity for viral hepatitis elimination and engaging stakeholders for grassroots advocacy to impact policy. Dr. Cohen is co-founder and director of Hep B United Philadelphia, a coalition to eliminate hepatitis B in Philadelphia. Nationally, she is chair of CHIPO: Coalition Against Hepatitis for People of African Origin; and co-chair of Hep B United, a coalition in 19 states to address and eliminate hepatitis B. Dr. Cohen is Associate Professor at the Baruch S. Blumberg Institute, and serves as adjunct faculty for the Jefferson School of Population Health, Drexel Dornsife School of Public Health, and Geisinger Commonwealth Medical College. Dr. Cohen received her MPH from Temple University and her DrPH in Community Health and Prevention from Drexel University School of Public Health.

Sue Dillon, Ph.D.

Co-Founder, President & CEO, Aro Biotherapeutics

Sue Dillon, PhD is co-founder, President and CEO of Aro Biotherapeutics, a start-up biotech focused on developing and commercializing Centyrins, a proprietary protein drug platform with the potential to revolutionize the delivery of diverse drug classes, including nucleic acids and genetic therapies. Sue has 30 years in executive leadership roles at pharmaceutical and biotech companies. She retired from her role as Global Therapeutic Area Head for Immunology at Janssen/J&J in 2017. During her 16+ year tenure at J&J, Sue led global Immunology R&D, and achieved numerous regulatory approvals for innovative antibody products for autoimmune diseases including REMICADE®, SIMPONI®, STELARA® and TREMFYA® that delivered combined end-user sales in excess of $10B. During her tenure, Sue built a robust Immunology development portfolio through internal discovery, and external licensing, and championed research into the emerging areas of the microbiome and immune repertoire profiling. Multi-disciplinary teams under Sue's leadership were twice recognized with the Prix Galien Award for PROMACTA® and STELARA®, each first in class medicines. Sue received her PhD in Immunology from Thomas Jefferson University in Philadelphia and completed a postdoctoral fellowship in Immunology at Duke University. Sue was named by FierceBiotech as one of the "Top Women in Biotech". Currently Sue is CEO of Aro Biotherapeutics and serves on the Board of Directors of the Wistar Institute.

Daniel Du, M.D., Ph.D.

SVP, Hua Medicine (Shanghai), Ltd.

Daniel Du has worked in the pharmaceutical industry for more than 20 years with broad experience in drug discovery, clinical development, and regulatory submission. He was instrumental in the discovery of multiple clinical candidates and played significant roles in multiple IND and NDA submissions when he was working in two of the fortune 500 pharmaceutical companies. He is also a skilled clinician and medical monitor for clinical studies, experienced in safety management, and authored the clinical sections for multiple NDA filings. He is the inventor of over 15 patents and authored over 20 manuscripts. Dr. Daniel Du received medical degrees from Beijing Medical University and PhD of Pharmacology & Toxicology from Albany Medical College, NY. He received US Education Certificates for Foreign Medical Graduates (ECFMG).

Tom (Tao) Du, Ph.D.

Medical Partner, Shenzhen Share Capital Co., Ltd.

Tom Du is currently working as a partner of Share Capital, and also as the Chief Consultant of Humphries Pharmaceutical Consulting. Dr. Du is a physician and also a scientist. He graduated from Tianjin Medical University (TMU), China. He got his training in medicine at TMU and in pathology at McGill University, Montreal. Before joining the US Food and Drug Administration (FDA) as a reviewing officer in 1994, he had two years of fellowship training at Harvard University. When he worked at the FDA, Dr. Du worked in the Division of Pulmonary, Allergy and Rheumatology Drug Products, and then worked in the Division of Oncology Drug Products. He reviewed more than one hundred INDs and NDAs. Since leaving the FDA in 2000, he has held several important positions in the pharmaceutical industry. He worked as Senior Director, Clinical and Regulatory Affairs, Hutchison Whampoa Company based in Hong Kong. He served as Acting Managing Director, China operations, and then worked as Senior Director, Global Regulatory Affairs at Ingenix Pharmaceutical Services, a UnitedHealth Group Company. Dr. Du has extensive experience in drug development and has held regulatory responsibilities in various therapeutic areas. He has been working as either project leader or project team member to help several American, European, and Asian drug makers develop their drug products and medical devices in the United States and China. Du's team has participated in more than 100 IND, NDA, BLA, ANDA and PMA submissions in the United States during the past 15 years.

Due to Dr. Du's experience in pharmaceutical development and CRO operation, he has been requested by various companies to design clinical development programs. Under his leadership, his team has helped more than 30 Chinese drug companies to submit ANDA or IND and initiate clinical trials for the development of new chemical, biological, herbal and generic drugs in the United States. Since the end of 2004, Dr. Du has also worked as a consultant for the American financial industry to evaluate the investment/business potentials of small and mid-sized pharmaceutical companies since 2004. He has served as a board member for two publicly listed biopharmaceutical companies in the North America. In the past few years, he has been working with several angel, VC, and PE investors to create and support newly established pharmaceutical companies in the United States and China. Dr. Du joined Share Capital in 2017 as a consultant, and then as a partner and a member of Investment Decision

Committee. He has been involved in various investment activities for pharmaceutical and medical device companies.

Dr. Du has published 19 articles in peer-reviewed scientific journals. He was a member of FDA committees for Botanical Drug Products and Clinical Pathology. He has received several awards from the FDA and pharmaceutical industry. He is also a frequently requested speaker for major international forums. In recent years, he organized and/or participated in symposia on drug development and pharmaceutical investment in the United States, Europe, China and Hong Kong. Dr. Du has given lectures to the Chinese CFDA officers and pharmaceutical experts in various training programs held by the North Carolina State University and Johns Hopkins University from 2011 to 2015.

Dennis Ford

Founder & CEO, Life Science Nation, Creator of RESI Conference

Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career finding, vetting and launching a myriad of technology-based companies. Over the last decade, he has worked extensively with global alternative investors and is deeply interested in getting funding for high-growth early-stage technologies. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. In today's context Dennis can connect early stage life science companies with 10 categories of global partners, thus making the finding of capital and distribution channels very efficient. Dennis created the Redefining Early Stage Investments conference series to facilitate an ongoing interactive dialog between buyers and sellers in the life science arena. Before LSN, Dennis was the President and CEO of a company that improved the way hedge fund and private equity fund managers raised capital and marketed their funds to investors. Ford is the author of *The Peddler's Prerogative* and *The Life Science Executive's Fundraising Manifesto*, two well-received sales and marketing books.

Sean (Xi-Yong) Fu, Ph.D., M.B.A.

President, Luye Boston R&D LLC.

Xi-Yong Fu is the President of Luye Boston R&D LLC. As a part of Luye's global R&D network, Boston R&D Center. He is responsible for developing innovative biologics assets and novel drug delivery technologies. Under the leadership of Dr. Fu, Luye Boston R&D Center has emerged as one of the preeminent R&D centers in the US established by a China biotech company. Prior to joining Luye, Dr. Fu was the President of Cureport Inc. Before that, Dr. Fu worded at Merck & Co., for 15 years with a wide range of responsibilities covering R&D, business development, finance and operational management. Dr. Fu is an experienced business professional. He managed the finance of a $300M late stage clinical portfolio at Merck. As a member of the clinical protocol review committee, Dr. Fu was responsible for reviewing and approving all Phase 2/3 clinical studies initiated by Merck including pivotal studies, many of which led to the approval of important therapeutics such as Keytruda, Zepatier, Zinplava, and Pifeltro etc. Between 2010 and 2011, Dr. Fu led the network integration after the landmark $42B merger between Merck and Schering. His work directly impacted 22 global sites and over 6000 scientists and shaped today's Merck global R&D network. Dr. Fu was also a member of the executive team within Merck that reviewed and approved all capital investments larger than $100M. Dr. Fu is a passionate scientist. Over the years, Dr. Fu directly contributed to over 15 preclinical development programs including the HIV integrase inhibitor Isentress® which has since become a pillar in HIV treatment with an annual global sale over $1.2 billion. Dr. Fu is an active member of the biotech community at large, serving as the President of Sino-American Pharmaceutical Professionals Association – Greater Philadelphia (SAPA-GP) between 2014 and 2015 and as SAPA Executive Committee member between 2012 and 2017. Dr. Fu is an honorable recipient of the Merck's highest innovation award, the Best Business Value Award; the Research Gold Award by Materials Research Society (MRS) and the prestigious William Oxley Thompson Award by The Ohio State University. Dr. Fu earned his PhD from The Ohio State University and his MBA from the Wharton School of Business.

Anya Harry, M.D., Ph.D.

Global Lead of Clinical Trial Diversity, GlaxoSmithKline

Anya Harry is the Global Lead for Clinical Trial Diversity at GlaxoSmithKline. Her passion for this area evolved from her experiences in clinical care, public health and drug development and research. Previously, she was a Director in Clinical Development providing leadership and medical support for early as well as late stage programs and device initiatives in the Respiratory Therapeutic Area. After several years as a pulmonary-critical care physician in private practice, Dr. Harry became a medical officer and subsequently a branch chief at the US Food and Drug Administration. Prior to joining GlaxoSmithKline, she directed a multidisciplinary team for a global consulting firm with a large focus on rare diseases. Dr. Harry received her MD, PhD from Mount Sinai School of Medicine and completed residency at Yale New Haven Hospital. She completed a combined pulmonary and critical care medicine training at the University of Pennsylvania and the National Institutes of Health. Dr. Harry has authored many peer reviewed articles and book chapters.

Chris Hansis, M.D., Ph.D.

Founder & CEO, Phase Clinical Services

Chris Hansis is the Founder & CEO of Phase Clinical Services, a full service CRO concentrating on Phase 0-II oncology clinical trials. Previously he was the Founder & CEO of the preclinical research services provider TransCell Science until its acquisition by BioIVT, for which he served as the Chief Scientific Officer. He was also Research Faculty, Principal Investigator and Director at the University of Southern California and New York University Medical Schools, focusing on generation of human embryonic stem and iPS cells and molecular lineage determination in preimplantation embryos.

Kevin Heyeck

Venture Partner, 6 Dimensions Capital

Kevin Heyeck joined 6 Dimensions Capital as Venture Partner in 2018 focused on creating and investing in healthcare and life science companies and is a director of Hibercell. He is a serial entrepreneur and biopharmaceutical executive with 25 years of experience building multiple venture-backed life sciences companies, leading business and corporate development. These companies include Allocure, Vitae Pharmaceuticals, and Pharmacopeia. He began his career with Harvard University's Office of Technology Licensing.

Laura Hong, M.D., Ph.D.

President, Klus Pharma Inc.

Laura Hong is currently the President of Klus Pharma, a subsidiary of Kelun Pharmaceutical Group. In this role she is responsible for overseeing both R&D and business development activities for the subsidiary. Prior to assuming this role, Dr. Hong was a Principal Investigator at Merck Research Laboratories. During her 14 years tenure at Merck, Dr. Hong led various initiatives for biologic drug development and contributed to more than 10 Merck vaccines,

including Vaqta, Gardasil4/9. Before beginning her industry career, Dr. Hong completed her fellowship at the Cleveland Clinic Foundation where she investigated in tumor angiogenesis and metastasis. She has previously served as the President of SAPA-Greater Philadelphia. Dr. Hong received her M.D. from China Medical University and Ph.D. from the Faculty of Pharmacy at Paris Descartes University in collaboration with the French National Institute of Health (INSERM).

Eric Hostetler, Ph.D.
Executive Director of Translational Imaging Biomarkers, Merck & Co.

Eric Hostetler received his Ph.D. in Organic Chemistry in 1998 from the University of Illinois Urbana-Champaign under the direction of John Katzenellenbogen. His dissertation focused on novel chemistry methods for incorporation of PET radioisotopes into small molecules. Eric continued in the field of molecular imaging with a postdoctoral appointment at the Washington University St. Louis School of Medicine in the Mallinckrodt Institute of Radiology. He subsequently joined Merck's Imaging Department in 2000. Since then he has had various roles in Imaging at Merck, including director of the PET tracer group, where he either led or contributed to the discovery of novel PET tracers for 12 different targets, primarily for the purpose of guiding neuroscience drug development. Currently Eric is the head of Translational Imaging Biomarkers at Merck, with a mission to discover, develop and implement novel imaging biomarkers to impact drug discovery and development.

Felix Hsu, M.B.A.
Senior Vice President, WuXi Advanced Therapies.

Felix Hsu is Senior VP and Global Head at WuXi Advanced Therapies located in Philadelphia, PA. He has nearly 31 years of experience in the life sciences industry and serves as an Advisory Board Member for the Jefferson Institute for Bioprocessing. He has mainly held executive and senior positions at the following companies: WuXi AppTec, Medtronic and Abbott Laboratories. He has studied at the University of Michigan – Stephen M. Ross School of Business with a Master's in Business Administration and Management.

Mike Hu, Ph.D.
Chief Development Officer, Rafael Pharmaceuticals

Mike Hu has 20 years of experience in clinical and pre-clinical R&D across multiple therapeutic areas: oncology, hematology, endocrinology, metabolic and infection diseases. He has taken leadership, management and mentoring roles, and received numerous awards. Dr. Hu is Chief Development Office at Rafael Pharmaceuticals, and in charge of R&D pipelines in both pre-clinical and clinical, as well as one of the key executives to re-build organization, team and culture since 2017. Before joining Rafael, Dr. Hu was at Jazz Oncology (2016-2017) and Novartis Oncology (2006-2016), and contributed to 18 drugs' clinical development, submissions, approvals, and life cycle management for multiple billion-dollar franchises. Before joining Novartis, he was at GSK Metabolic & Viral and contributed to 2 drugs from discovery, pre-clinical development to IND. Before joining the industry, Dr. Hu was in academia and served on the editorial board for 4 journals, peer reviewer for 30+ journals, and consultant for 2 medical groups. He received B.S. in Pharmacy and Ph.D. in Pharmaceutical Sciences at Shenyang Pharmaceutical University, China, with an international exchange program at University of Tokyo, Japan. Dr. Hu has authored 52 journal papers, 33 conference abstracts, 5 patents, 2 proceedings, and 1 book chapter, and been invited as speaker at numerous conferences.

Frederick (Rick) Jones, M.D., M.B.A.
Partner, BioAdvance

Frederick (Rick) Jones is a life science investor, entrepreneur and physician with extensive experience in biopharmaceuticals and healthcare. Before joining BioAdvance, Rick was a Director at Broadview Ventures, a philanthropic venture investor with a mission to support early stage companies with potential breakthrough technologies in cardiovascular disease. At Broadview he participated in all aspects of the investment process including sourcing opportunities, diligence, negotiating deal terms, supporting portfolio companies and serving on corporate boards. Before Broadview, Rick held a variety of roles in startup and medium sized biotech companies. He was CEO of Anchor Therapeutics, a company with a lipidated peptide platform technology to modulate refractory GPCR targets. Earlier, he was head of the pharma business unit at Devgen, a Belgian biotechnology company. Rick started his biotech career as Vice President of Business Development at BioRexis, a company with a platform technology to extend the half-life of peptides, where he participated in the successful sale of the company to Pfizer. Preceding his biotech positions, Rick worked in big pharma at Wyeth Pharmaceuticals, where he held positions in Global Business Development and Global Medical Affairs. Rick began his career as an internal medicine physician, most recently as Assistant Professor of Clinical Medicine in the University of Pennsylvania Health System. Prior to that he was on staff at the Lahey Clinic and served in the Naval Medical Corps at Long Beach Naval Hospital. Rick received his BA, MD and MBA degrees from the University of Pennsylvania.

Don Kraft
EVP, Strategic Initiatives, ICON PLC

Don Kraft is EVP of Strategic Initiatives, focused on developing ICON's capabilities and performance as a partner to our customers. Mr. Kraft joined ICON in 2012 and served as the EVP of Human Resources before transitioning to this role in 2016. Mr. Kraft has over 30 years of experience in the Pharmaceutical and CRO industries, including ten years as the Human Resources leader at Covance, and over ten years at Abbott Labs in a variety of leadership roles. Mr. Kraft has a wide breadth of experience in human resources and organizational development / capability building and was part of negotiating and implementing some of the industries early groundbreaking partnerships. Mr. Kraft has a Bachelor's in Business Administration from Villanova University and a master's in management from Northwestern University.

Amy Leader, Dr.P.H., M.P.H.
Associate Professor, Department of Medical Oncology, Thomas Jefferson University

Amy Leader, DrPH, MPH, is an Associate Professor in the Division of Population Science, Department of Medical Oncology at Thomas Jefferson University in Philadelphia, where she also teaches behavioral science and research methods courses in the MPH program at the Jefferson College of Population Health. She is a full research member

of the Sidney Kimmel Cancer Center at Jefferson and is also the Director for Community Outreach and Engagement. Her research, broadly speaking, is in the areas of cancer prevention and control, health communication, and community-engaged research. Currently, she is the PI of two NIH funded studies, one investigating barriers to HPV vaccination in Philadelphia and the other to conduct a community assessment of cancer knowledge, attitudes, and behaviors among residents in the Greater Philadelphia area. She is on the Public Health Section's Executive Committee at the College of Philadelphia and last year co-founded the Greater Philadelphia HPV Immunization Collaborative, which meets quarterly at the College. She is a member of the PA Department of Health's Cancer Control Leadership Team, and a journal editor for BMC Public Health.

Feng (Frank) Li, Ph.D.

President, Alliance Pharma

Feng Li, Ph.D. is president and one of the founders of Alliance Pharma. He obtained his Ph.D. in Bioanalytical Chemistry jointly from Canadian Doping Control Centre and Concordia University. Subsequently he conducted post-doctoral training in Biomedical Mass Spectrometry Facility at Mayo Clinic. Furthermore, Dr. Li also has a BS in Pharmacy and a MS in Medicinal Chemistry. Professionally, he has held responsible roles in the area of drug discovery metabolism at Phoenix International (a major CRO), in the Drug Analysis group in the Department of Drug Metabolism and Pharmacokinetics (DMPK) at GSK Pharmaceuticals and in the Drug Metabolism group at Cephalon (Now Teva). Dr. Li has extensive DMPK experience in both the drug discovery and development. He is a recognized expert in the field of bioanalysis and DMPK. He has more than 20 years working experience in CRO, pharmaceutical and biotech industries. Under his team's leadership, Alliance Pharma was recognized as:

2014 ─ The Philadelphia 100 ® Fastest Growing Companies
2015 ─ The Philadelphia 100 ® Fastest Growing Companies
2016 ─ SmartCEO's Future 50 Companies
2017 ─ SmartCEO's Future 50 Companies Development

Xiaoshuang (Shell) Li, M.D.

Chief Medical Officer and Chief Operating Officer, Hengruiyuan

Shell Li has more than 20 years of experiences in drug/biological New products clinical development (from phase I to IV studies) in the United States, especially in the field of oncology and vaccines development. In 1995, she joined Merck as a Scientist, then Clinical Project Lead to participate in the pivotal trial of rotavirus 60,000 enrollment and represented the company participated in the FDA Advisory's Committee Meeting. She then joined Amgen as the Medical Director responsible for Aranesp, Sorafenib life cycle management, and multiple phase I to III clinical studies. In 2011, as the Head of Development for Greater China area, she represented Novatis Vaccine returning to Shanghai. Later, she joined Boehringer-Ingelheim as The Head of Clinical Research and Operations, responsible for all clinical studies in China and Hongkong, in particular, responsible for afatinib and nidanib pivotal trials in China. She has extensive experience in building and managing a development team with a very in depth understanding of clinical development.

Irene Liu, M.B.A.

Financial Advisor & Portfolio Manager, Morgan Stanley Wealth Management

Irene Liu is a Financial Advisor and Portfolio Manager with Morgan Stanley in Manhattan, New York. Her practice is focused on providing investment planning and access to lending services to high net worth individuals and families, and small to medium sized businesses. She customizes plans for each client's resources, tax circumstances, estate plan, and risk tolerance, with the goal being to maximize after-tax returns using an appropriate asset allocation. Irene immigrated from Taiwan at age eight and truly understands the challenges of first-generation immigrants from establishing themselves to dealings with parents who don't understand US culture, investments or taxes. Fluent in mandarin, she works closely with first generation immigrant families whose patriarch or matriarch remain in China, Taiwan, or Hong Kong. Prior to joining Morgan Stanley, Irene was a Director at BNP Paribas and Bear Stearns responsible for Structured Products Origination and Sales. Her clients were regional broker/dealers and Financial Advisors. Irene has an MBA with a concentration in Finance from Wharton Business School and MS and BS in Operations Research from UC Berkeley. When she has some personal time from entertaining her two young children, she enjoys swimming, deal-hunting online, British period dramas, and movies. Irene lives on the Upper West Side of Manhattan with her husband, daughter, and son.

Jie (Jay) Liu, M.B.A.

Managing Director, Torreya

Jie Liu, a Managing Director at Torreya, leads the company's operations in China. He has over 20 years of experience in the pharmaceutical and healthcare industries, mostly focused on global licensing and M&A. In his current role, Jie is active in a variety of transactions in both branded and generic opportunities in the US and China. In 2018 Jie completed 4 transactions into China. Jie joined Torreya in 2016 from Heritage Pharma, a subsidiary of Emcure Pharmaceuticals, where he was Vice President, Business Development and Licensing. Previously, he was Senior Director, Global Business Development at Teva, and held business development positions with increasing responsibilities at J&J, Cephalon, and Auxilium. Notable transactions on which Jie advised prior to joining Torreya include Teva's $3.5 billion acquisition of Auspex; Teva's acquisition of Labrys Biologics for up to $825 million, including $200 million upfront; Teva's collaboration with Microchips in implantable medical device for $35 million in equity investment and technology access fee; Testim co-promote between Auxilium and GSK; Provigil co-promote between Cephalon and Takeda; Cephalon's $350 million stem cell deal with Mesoblast for $130 million upfront and a $220 million equity stake; Cephalon's acquisition of ChemGenex for $231 million; and Cephalon's acquisition of Salmedix for $160 million. Jie received a B.A. from Tianjin University in China and an M.B.A. from the Wharton School at the University of Pennsylvania.

Jan Joseph Melenhorst, Ph.D.

Adjunct Associate Professor, Pathology & Laboratory Medicine, University of Pennsylvania

Jos Melenhorst graduated with a bachelor's degree in continuing education from Tilburg Fontys Teacher's College, the Netherlands, a master's degree in Medical Biology from the Nijmegen Catholic University, the Netherlands, and a Doctor of Philosophy from the Leiden University, the Netherlands. After a post-doctoral fellowship followed by a staff scientist appointment at the National Institutes of Health. He was recruited to the University of Pennsylvania in 2012 by Dr. Carl June, first as Deputy Director of the Clinical Cell and Vaccine Production Facility and later as the Director of Product Development & Correlative Sciences. In this role, he was at the cusp of the first ever CAR T cell therapy approved by FDA: Kymriah. Dr. Melenhorst contributed significantly to the evolution of the CAR manufacturing process and to in-depth mechanistic studies into the immunobiology of CAR T-cell therapies, work that was published in high impact journals such as Nature, Nature Medicine, Cancer Discovery, Science Translational Medicine, and the New England Journal of Medicine. His work received the National Clinical Research Achievement Award from the Clinical Research Forum in 2019, which recognizes the ten most outstanding clinical research accomplishments in the United States during the preceding twelve months.

Dr. Melenhorst is interested in understanding and improving the anti-tumor efficacy and safety of adoptively transferred CAR-modified T cells through correlative, mechanistic, and pre-clinical studies, and partly through functional genomics approaches. This includes studying human T cell biology, the tumor microenvironment, and the genetic and biological impact of lentiviral vector-mediated mutagenesis in CAR T cells from treated patients.

Xiaofeng Meng, Ph.D., M.B.A.

CEO, Epic Pharma
CEO, PuraCap Pharmaceutical

Xiaofeng Meng serves as the CEO of Epic Pharma in NY and PuraCap Pharmaceutical in NJ since March 2018. Prior to this role, Dr. Meng was General Manager of Humanwell PuraCap Pharmaceutical (Wuhan) LLC., a dedicated softgel manufacturing facility for two years. From 2011 to 2016, Dr. Meng was the VP of Quality & Regulatory Affair for PuraCap Pharmaceutial. Dr. Meng's academic degrees include: Ph.D and MBA from Rutgers University in New Jersey, and a Master's degree in Pharmaceutical Science from the Shanghai Institute of the Pharmaceutical Industry, Shanghai, P.R. China patients

Camilo Moncada, Ph.D.

Director of Custom Research, Rockland Immunochemicals

Camilo Moncada obtained his PhD in Biochemistry at the School of Medicine at Temple University while working on proteomics approaches for the discovery and characterization of novel biomarkers and potential targets to diagnose and prevent lung disease. He completed his post-doctoral training at UCONN Health Center working on cell reprogramming and stem cell differentiation to enable lung tissue regeneration. He has authored and co-authored several publications in immunology, lung disease, proteomics and regenerative medicine. Dr. Moncada joined Rockland Immunochemicals five years ago as a senior scientist providing technical guidance and support to our lab staff in different areas including molecular and cellular biology, protein science and immunoassays. Since then he has also performed as the Head of the Custom Polyclonal Antibody Development group and Director of Antibody Validation and QC. Since 2016, as the Director of Custom Research, he has been leading the design and execution of several custom projects and more recently, the in-house development of bispecific antibodies.

Henry (He) Sun, Ph.D.

Vice President, Tasly Holding Group, Co. Ltd.
Co-founder and CEO, Tasly Pharmaceuticals, Inc., USA

Henry Sun is the Vice President at Tasly Holding Group, and the Co-founder and CEO of Tasly Pharmaceuticals, Inc. of USA. Dr. Sun graduated from Shanghai Medical University in 1982 and received his Ph.D. in Clinical Pharmacology and Biopharmaceutics from the University of Connecticut in 1993. Dr. Sun then served at the US FDA as a regulatory reviewer, and was promoted to be one of the very top-ranked Expert Reviewer in 2000 after 7 years of federal services. Since 2006, Dr. Sun joint Tasly Group as the Vice President, focusing on innovative drug developments, international R&D collaborations, and business developments. During the past 13 years, Dr. Sun leads his group successfully registered over 20 new drugs in 32 countries and made a historical milestone to develop the first-and-only multi-herbal drug product to complete its clinical phase III development stage in the United States and is developing several multi-herbal drug products, herbal extract injectable, small molecules, generic drugs, as well as biologic products at phase I or phase II stages in the USA. Dr. Sun is also very active in developing business collaborations. He established and is serving as the Board Members of 5 international R&D Joint Ventures, and achieved 28 worldwide business deals worth $2 billion with those very top pharmaceuticals firms. Dr. Sun currently also serves as a professor at the School of Medicine of Jiaotong University of China, and the Adjunct Professor at University of the Pacific, San Francisco, USA. Dr. Sun has more than 100 peer-reviewed publications in medical and pharmaceutical journals and is frequently invited as a keynote speaker at many international conference.

Huabin Sun, M.D.

Senior Medical Director, Clinical Research & Development, Janssen Pharmaceuticals

Huabin Sun has extensive knowledge and experience in drug safety/Clinical Development. As a physician/scientist, Huabin has worked in the fields of cardiology, cardiac electrophysiology and cardiac arrhythmia, including clinical practice in the China and research in the US. Huabin's industrial experience including drug discovery in the antiarrhythmia/antihypertension, pre-clinical cardiovascular safety, pharmacovigilance and clinical development. Huabin's clinical safety experience expands from single case processing, aggregate safety analysis, signal detection and evaluation, risk identification and minimization, ad-hoc and periodic safety report, worldwide filing, post-marketing safety management and safety query response. Huabin's clinical development experience includes design and execution of pivotal clinical trials.

Timothy W. Victor, Ph.D.

Global Head and Vice President of Biostatistics, ICON PLC

Timothy W. Victor has over 25 years of industry and academic experience. This experience includes work in all phases of clinical development, post-marketing, epidemiology, health economic/outcomes research, and psychometrics. He is on the faculties of the University of Pennsylvania, and Philadelphia College of Osteopathic Medicine, where he teaches courses in experimental design, advanced statistical methods, and measurement theory at the graduate level. He has recently joined ICON PLC, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, as the Global Head and Vice President of Biostatistics.



Dai Wang, Ph.D.

Principle Scientist, Merck & Co.

Dai Wang received his PhD degree in virology from Cornell University and completed his postdoctoral training under the supervision of Tom Shenk at Princeton University where he studied cytomegalovirus pathogenesis and cell tropism. His work led to the establishment of an epithelial cell infection model, discovery of the pentameric glycoprotein complex, and importantly, a new concept for potential CMV treatment and prevention. In 2007, Dai joined Merck Research Laboratories to pursue the development of a CMV vaccine. In addition to his work on CMV vaccine, he currently leads several discovery efforts on other viral vaccine candidates and approaches.

Aaron Weinstein

Senior Director of Validation Services, Integrated Project Services

Aaron Weinstein is Senior Director of Validation Services at Integrated Project Services. He has over 20 years' experience in commissioning, qualification and validation within the pharmaceutical and biotech industries. Mr. Weinstein's experience includes: Planning and executing commissioning and qualification projects, preparation of master plans, performing quality risk assessments, quality audits and remediation. Mr. Weinstein has a broad range of experience in the facilities, utilities, equipment and automation related to CAR-T manufacturing, biotech bulk

manufacturing, bulk drug manufacturing and specialized packaging. At IPS, Aaron's principal responsibilities include project development and management, compliance consulting, business development, and departmental leadership. Aaron earned a BA in Interdisciplinary Studies (Chemistry/Biology) from Touro College. Aaron is an active member of ISPE and a member of Supply Chain, Operations and Packaging Excellence (SCOPE) Community of Practice Steering Committee.

J Fraser Wright, Ph.D.

Chief Technology Officer, Axovant Sciences
Principle, Wright Biologics Consulting Committee

J Fraser Wright received his PhD in 1989 from the University of Toronto (Biochemistry) for studies characterizing the interaction of complement with IgM, and completed post-doctoral studies at INSERM / CENG Grenoble, France in molecular immunology focused on antigen processing and presentation. He was awarded an CRCS/ MRC Scholarship in 1993, with faculty appointment at the University of Toronto. In 1996 he moved to industry as a Scientist at Pasteur Sanofi working on the development of cancer immunotherapies, and subsequently as Director of Development and Clinical Manufacturing at Avigen, a gene therapy company that pioneered rAAV based investigational products for hemophilia and Parkinson's Diseases. In 2004 he returned to academia, establishing the Clinical Vector Core at the Center for Cellular and Molecular Therapeutics at Children's Hospital of Philadelphia, gaining faculty appointment at the University of Pennsylvania Perelman School of Medicine as professor of Pathology and Laboratory Medicine. Dr. Wright has contributed to several clinical development programs in gene therapy, including those for Luxturna and Kymriah, the first gene therapies for a genetic (RPE65 deficiency) and non-genetic (CAR-T immunotherapy) disease, respectively, approved in the United States. He is a Co-founder of Spark Therapeutics, served as Chief Technology Officer at Spark and Axovant Gene Therapies, and is Principal at Wright Biologics Consulting Committee



Zhenhua Wu, Ph.D.

Founder & CEO, Landes Therapeutics Inc.

Zhenhua Wu is a senior discovery and development leader with more than 20 years' experience and a deep understanding of pharmaceutical R&D value chain. He has extensive R&D experience in small molecule, vaccine and cell and gene therapy. Dr. Wu is the founder and CEO of Landes Therapeutics Inc., a start-up company focusing on the development of innovative cell and gene therapies for high-need patients. Prior to this, he was the CEO of NeuExcell Therapeutics, overseeing all corporate operations and business activities. Previously he was the Vice President, Head of Preclinical Development of United Neuroscience, and oversaw the strategy and execution of preclinical research and development. He served as a director of the neuroscience therapeutic area at GlaxoSmithKline, where he led cell and gene therapy and small molecule projects for the treatment of neurodegenerative and neuroinflammatory diseases. Dr. Wu had worked in various functional areas in Merck & Co. for ten years where he led various neuroscience projects and delivered several preclinical candidates and served as a global externalization lead. Zhenhua received his Ph.D. degree in neuroscience from University of Rochester and M.S. degree in cell biology from Shanghai Institute of Cell Biology, Chinese Academy of Sciences. He has published extensively in the field of neuroscience including publications in prestigious journals such as Nature, Nature Medicine, Neuron and Stroke. He is also a recipient of Hugh Davson Distinguished Award in Neurovascular Biology. Zhenhua Wu served as the President (2016-2018) of Sino-American Pharmaceutical Professional Association – Great Philadelphia (SAPA-GP).

Jenny Xie, Ph.D.

Director, Discovery Immunology, BMS

Jenny Xie is a Director of Discovery Immunology at Bristol Myers Squibb (BMS). She has over 18 years of pharmaceutical industry experience in discovery of both small molecules and biologics for immune disorders. Jenny has an extensive experience in leading projects of various discovery stages and in managing matrix teams. She has successfully led a project from discovery and preclinical development to clinical trials which have shown promising clinical results. Jenny is a trained Immunologist and pharmacologist. In her current job, she leads a team of in vivo biologists to assess compound properties in PK/PD and pharmacological efficacy in disease models in the areas of autoimmune diseases and cancer. Under Jenny's leadership, her team has contributed over 25 project transitions from discovery to development. In addition, Jenny serves as the BMS lead for the Tsinghua/BMS alliance. She also works extensively with BMS/India in vivo team and various CRO companies. Jenny received her bachelor's degree in Biology from Fudan University and her Ph.D. in Immunology from Boston University School of Medicine. She completed her postdoctoral training at Harvard University and worked at Merck Research Labs for 5 years as a research fellow before joining BMS in 2005.

Li Yan, M.D., Ph.D.

Chief Medical Officer, Brii Biosciences

Li Yan, M.D., Ph.D., is Chief Medical Officer at Brii Biosciences. He has overall responsibility for clinical development, regulatory affairs, medical affairs, pharmacovigilance, quality, and other related functions. He is accountable for developing and driving execution of clinical development programs and registrations.
Prior to joining Brii Biosciences, Dr. Yan was Vice President and Head Unit Physician of GSK Oncology where he oversaw global development of oncology assets focusing on immunotherapy, cancer epigenetics, and cell therapy. Prior to his tenure at GSK, he was Executive Director at Merck responsible for clinical development of oncology, respiratory and immunology, infectious diseases, and vaccines in emerging markets including the development of immunotherapy Keytruda (pembrolizumab) in China and other emerging markets countries. Dr. Yan started his industry career with Centocor, a Johnson & Johnson company, leading both discovery and clinical development of anti-cancer biologics. He has published over 80 manuscripts and book chapters.
Dr. Yan received his medical degree from Medical College of Peking University and a Ph.D. from the University of Kansas Medical Center. He completed his post-graduate training at Beijing Cancer Hospital, Peking University, and Boston Children's Hospital/Harvard Medical School. He is also an alumnus of the Harvard Business School enterprise executive program. Dr. Yan holds adjunct professorships at Peking University and Yonsei University, and he is Managing Director of the US Chinese Anti-Cancer Association. He also serves in a number of scientific committees of Chinese Anti-Cancer Association and Chinese Society for Clinical Oncology.

Qingrui You, Ph.D.

Process Director, OBiO Technology (Shanghai) Corp., Ltd.

Qingrui You is the Director of Process Development and GMP manufacturing Department in Obio Technology in Shanghai since 2017. Focusing on virus and plasmid product, he leads team to work on Chemistry, Manufacturing and Controls (CMC) projects for Investigational New Drug Application (IND) project. So far, his team has finished more than 10 projects for either Investigator Initiated Trails (IIT) or IND, and has experience in Micro ring plasmid, Adeno-associated virus (AAV), Lenti Virus (LV), Vaccinia Virus (VV). Based on single use technology Flex FactoryTM, his team has established a fully validated GMP facility. The team can provide Contract Development and Manufacturing Organization (CDMO) service for scientific research institutions and pharmaceutical companies engaged in gene therapy and cell therapy. Prior to Obio Technology, Dr. You served as senior PD scientist in General Electric (GE). His led several process development and pilot scale up projects, including DNA plasmid, protein, antibody and virus.

Catherine Zhang, M.B.A.

International Financial Advisor & Portfolio Manager, Morgan Stanley Wealth Management.

Catherine Zhang is an international financial advisor at Morgan Stanley, working with higher net worth families, as well as institutions in the U.S., Asia and other countries. Prior to her current role, she had been as a Vice President at Bank of America Merrill Lynch's investment bank headquarter in New York for 9 years, with experience in both trading and investment banking divisions. Catherine holds an MBA from NYU Stern School of Business, a Master in Operations Research from the University of Florida, a Master and a Bachelor's in physics from Northwest University in China.

Linghang Zhuang, Ph.D.

Head of Chemistry, Eternity Biosciences Inc.

Linghang Zhuang is the Head of Chemistry at Eternity Bioscience, a subsidiary of Hengrui Medicine. He joined the company in 2017 and took the responsibility of overseeing several drug discovery programs. Prior to joining EBI, Linghang was a Director of Chemistry at Vitae Pharmaceuticals Inc., an Allergan affiliate. During the 11 years' tenue, he led discovery efforts in autoimmune disease, diabetes, cardiovascular disease and oncology areas. He supported development and IND enabling activities and advanced 3 compounds to human clinical trials. Before joining Vitae, Linghang was a Research Fellow at Merck, working on anti-infectious disease and CNS programs for 7 years. Over his career, Linghang has co-authored more than 80 scientific papers and patent applications. Linghang received his Ph.D. in Chemistry from the University of Pennsylvania, under the guidance of Professor Amos B. Smith III and B.S. in chemistry from University of Science and Technology of China.

.

Organizing Committee Members

Tiger Bee
Han Dai
Laura Hong
Bo Liang
Fang Shen
Huaping Tang
Danhui Wang
Shuang Wu
Li Yan
Qiangnan Zhang
David Cragin
Yu Gao
Yufeng Li
Yue Liu
Mengjie Si
Yeqing Tao
Zhiyun Wen
Di Wu
Jing Yang
Xinjun Zhang
Haifeng Cui
Dennis Gross
Yutai Li
Yangsi Ou
Yongshao Su
Hui Wang
Zhenhua Wu
Jian Wu
Haichen Yang
Zhipeng Zheng
Li Cui
Pengbo Guo
Yin Liang
Chun Shao
Hao Sun
Lu Wang
Hao Wu
Xin Xin
Hanghang Zhang

Program Directors

Haifeng Cui Haichen Yang

Art Design and Brochure Editing

Pengbo Guo Jianting Shi
Mengjie Si Shuang Wu
Hao Wu Di Wu
Junyang Xian

Pharma
绿叶制药

Passionate for Life

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has reached a high level international standard in advanced drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.

Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., Europe and Japan, as well as fast growing emerging markets.

Contact Us:
Luye Pharma Group, Ltd502 Carnegie Center Drive, Suite 100 Princeton, NJ 08540, USA
Office: +1-609-212-0613 Email: hr@luye.cn

Luye Boston Research and Development LLC
19 Presidential Way, Suite 304, Woburn MA 01801

让患者早日用上更好药物

Making Better Medicines Available to Patients Sooner

先声药业是中国领先的研发驱动型制药公司，拥有“转化医学与创新药物国家重点实验室”，通过自主研发与对外合作相结合，聚焦肿瘤、神经、风湿免疫、感染等重大疾病领域，致力于让患者早日用上更好药物。

Simcere Pharmaceutical Group is a Chinese pharmaceutical company with 5000 employees. It is amongst the pioneering companies to develop and launch innovative drugs in China. Simcere is actively looking for innovative drug candidates in all stages in the therapeutic areas of Oncology, CNS, Autoimmune and Infectious disease, as well as technology platforms in Cell Therapy and Artificial Intelligence. Simcere now has a significant global presence, including US and Europe.

科伦药业
KELUN PHARMACEUTICAL

KLUS PHARMA

- Kelun Pharmaceuticals, founded in 1996, is a top 10 Chinese pharmaceutical company with over 100 subsidiaries including KLUS Pharma in New Jersey
- Focusing on unmet medical needs involving cancer, liver, cardiovascular , and autoimmune diseases.
- KLUS Pharma specializes in therapeutic antibodies
- Immediately openings:
  - Director, Therapeutics Antibody Discovery
  - Sr. Scientist, Antibody Engineering
  - Scientist, Target Discovery & Innovation
  - Associate Scientist, Antibody Engineering
  - Associate Scientist, Bioassay

Please contact :
HR@kluspharma.com
8 Clarke Drive, #4, Cranbury, NJ 08512
www.kluspharma.com

PHASE CLINICAL SERVICES

Your complete resource for oncology clinical trials

1 IN 5 TRIALS FAIL DUE TO LOW ENROLLMENT

1 IN 2 HAVE INSUFFICIENT ENROLLMENT

4 IN 5 TRIALS FAIL TO MEET TIMELINES

LET US MANAGE RISK FACTORS TO ENSURE YOUR SUCCESS

- Gain exclusive access to our global network of over 10 hospitals and 51,000 available oncology patients
- Our fee rates are substantially below US averages
- We offer a full range of laboratory and research management services

See potential enrollment for your clinical trial:

PHASE CLINICAL SERVICES
575 LEXINGTON AVE
NEW YORK, NY 10022

INFO@PHASECLINICAL.COM
(800) 838-5285
PHASECLINICAL.COM

JIANGSU HENGRUI MEDICINE

Science & Technology for a Better Life

The Largest Publicly Traded and a Leading Biopharma based in China with Growing Global Footprint

Overview

A Global Biopharmaceutical Company Founded in	1970	Listed on the Shanghai Stock Exchange since	2000
Market Capitalization[1]	$41bn		
2017 Revenue	$2.6bn	Annual Revenue Growth	26%
2017 Net Income	$0.6bn	Net Income Margin	23%
Annual R&D Investment	15%	Novel Biologics & Small Molecules in Clinical Development	35
		CFDA approved NMEs	4
		ANDAs in U.S., EU and Japan	10+

1. As of April 19, 2019.

Broad Capabilities in China and Globally

- 10 research centers worldwide, with > 3,200 dedicated researchers
- > 70 internally developed NMEs
- > 1,000 clinical experts leading >100 clinical trials worldwide
- Commercial-scale small molecule and biologics manufacturing facilities
- > 15,000 in house sales representatives covering >5,000 hospitals in China

Locations

China	United States	Australia	Japan	Germany
Beijing Chengdu Hongkong Lianyungang Nanjing Shanghai Suzhou	New Jersey	Sydney	Nagoya	North Rhine-Westphalia

Websites:
Jiangsu Hengrui Medicine Co. Ltd: http://www.hrs.com.cn/english/
Hengrui Therapeutics Inc.: http://www.hengruitherapeutics.com/
Eternity Bioscience Inc.: http://www.eternitybioscience.com/
eVenus Pharmaceutical Laboratories Inc.: http://www.evenuspharma.com/
Renascent Biosciences LLC: https://www.renascentbio.com/

CDMO Introduction

Since 2016, OBiO has established comprehensive strategic cooperation with GE Healthcare Co., Ltd. (GE Healthcare) on gene therapy. Obio has invested more than $20M to build the GMP virus manufacturing platform with 5000 m². The platform is cooperating with a number of gene therapy or cell therapy drug companies in CDMO projects involving products including adeno-associated viruses, lentiviruses, adenoviruses, poxviruses, herpes simplex virus，and naked plasmids.

OBiO professional team has CRO/CDMO service experience:

1. GMP Virus for Investigator Initiated Clinical Trail
2. Investigational New Drug Application Total Solution
3. GMP Manufacturing Service for Recombinant Virus

OBiO 和元上海

OBiO Technology (Shanghai) Corp., Ltd. GMP Address: BLD.9, No. 100, BanXia Road, Pudong, Shanghai, China

Telephone: 400-151-5198 021-3160 1005 Email: oobio@obiosh.com Stock Code: 839702

Website: http://www.oobio.com.cn Address: BLD.19, No. 908, Ziping Road, Pudong, Shanghai, China

Primera

Primera Analytical Solutions Corp.

ONE STOP SOLUTION FOR YOUR CONTRACT ANALYTICAL NEEDS

Primera Analytical Solutions is a contract analytical laboratory offering a broad number of services such as Method Development and Validation, Impurity Studies to include Genotoxic Impurities (LCMSMS, GCMS, ICPMS), Extractables & Leachables, Stability and Photostability Studies, Dissolution Studies, Abuse-Deterrent Studies, Product Release Testing, Method Transfers, Inhalation Products, and Raw Material Testing. We are in great standing with the FDA with regard to GMP and GLP.

In addition, our bioanalytical services for both small and large molecule drugs cover Assay/Method Development and Validation, PK/PD sample analysis, Metabolite Characterization, Bioavailability and Bioequivalence Studies, Impurities by ELISA, Anti-Drug Antibody Assays (ADA), Peptide Mapping and so much more. At Primera, quality and client satisfaction are our primary objectives. Our expert team strives to provide our customers with timely reports as well as quality of services unsurpassed in the industry.



YOURWAY TRANSPORT
TIME SENSITIVE
BIOPHARMA SERVICES

A Fully Integrated Service Offering

Clinical Packaging & Global Premium Transport

Comparator Sourcing
Primary & Secondary Packaging
Global Depot Network
Global Storage & Distribution
Cold Chain Management
Shipping & Logistics
Direct to Patient
Time Sensitive

For more info please contact:
info@yourwaytransport.com
1.610.395.9198 or Toll Free 1.888.778.4555

www.yourway.com

WE SEQUENCE, YOU DISCOVER

From Biomarker discovery and validation to Companion Diagnostics, BGI is the Pharma Services Organization of choice for 18 of the top-20 Pharma companies.

Pharma Services

BGI's Experience and Network:

- √ Global partnership experience
- √ Quality and Regulatory compliance
- √ Access to patients in China
- √ Access to government and clinical resources in China
- √ Validated cancer panels

Sequencing Services

Global NGS Services:

- √ Genomics
- √ Transcriptomics
- √ Epigenomics
- √ Immune Repertoire
- √ Bioinformatics

To learn more about how BGI's experience can put your Drug Discovery projects in overdrive, come talk to us at our booth, or visit our web site www.bgi.com

BGI
GLOBAL GENOMIC SERVICES

Alliance PHARMA

Your Trusted Partner

CORE CAPABILITIES

Alliance Pharma is a Contract Research Organization (CRO) **specializing in Drug Metabolism and Pharmacokinetics** (DMPK) and **bioanalytical services** for both small and large molecules. It is our goal to help you through the process of taking your drug from pre-clinical and clinical trials to market as fast and as problem-free as possible.

Our extensive and diverse experience includes:

- LC-MS/MS bioanalysis of small and large molecule drugs
- LC-MS/MS protein characterization
- Immunoassays to support pharmacokinetic and toxicokinetic studies
- Immunogenicity studies including antidrug antibody (ADA) and nAb assays
- Biomarker assays through preclinical and clinical development
- CLIA accreditation to support diagnostic biomarker studies
- In vitro drug metabolism studies
- AAALAC-accredited vivarium for preclinical in vivo PK studies
- Sample storage facilities

AlliancePharmaco.com

Alliance PHARMA

Acro BIOSYSTEMS | Recombinant Proteins for Biopharma Industry

Human CD20 Full Length Protein

FGL1 : A Novel Immune Inhibitor of LAG-3

MABSOL® Biotinylated Proteins

Suitable for Detection of CAR Expression

ACROBiosystems is a leading manufacturer of recombinant proteins. We provide high-quality protein reagents and technical support to the biopharma community. Our catalog includes biotinylated proteins, immune checkpoint proteins, Fc receptor proteins, CAR-T cell therapy targets, biosimilar drug targets, anti-idiotypic antibodies, and quantitative analysis of mAb in serum.



WWW.RESICONFERENCE.COM

LIFE SCIENCE NATION
Connecting Products, Services & Capital

McDermott
Will & Emery

STETSON FAMILY OFFICE

BioKatalyst

Inspire Biopharma Commercial Leadership

BioKatalyst is a nonprofit professional organization of American business leaders with Chinese heritage focused on the commercial areas of life sciences industry in the US and globally.

www.biokatalyst.org

Friday, May 31, 2019

Note

INTRODUCTION OF HIGH-TECH ZONE AND BIO-INDUSTRY



Chengdu High-tech Zone was set up in 1988 and was approved as the first national high-tech zone in 1991. In 2006, CDHT was set up to be the "world-class high-tech zones" pilot zone approved by the Ministry of Science and Technology; in 2015, it is the first national independent innovation demonstration zone in western China, and it is the core area of Sichuan Provincial Comprehensive Innovation Reform and Free Trade Experimental Zone.

With an area of 657 km^2 (excluding 44 square kilometers in cooperation with Chengdu Shuangliu Zone), CDHT includes 4 parts, Tianfu International Aerotropolis, southern park, western park and Tianfu International Bio-town. Based on these four functional industrial areas, relying on 3 major industries: digital information, biomedicine and new economy, CDHT makes efforts in cultivating and developing innovative industrial clusters, constructing industrial ecosphere and innovate ecological chain, and creating a modern industrial system with global competitiveness.

In 2018, CDHT realized a bioindustrial value over 40 billion yuan, of which the industrial output value was 21.2 billion yuan, increased by 22.2%. 26 100 million-yuan varieties were realized, accounting for 34.2% of Chengdu's 100 million-yuan varieties. CDHT has the only National Major New Drug R&D Project Technology Transfer & Commercialization Pilot Base, rising CDHT to the 6th place in the overall National Biopharmaceutical Industrial Park. Gathering international giants like Sanofi, Allergan, Brilliant Pharmaceutical Group, Chengdu Rongsheng Pharmaceuticals Co. Ltd., Di'Ao Group, Maccura Biotechnology Co., Ltd. and Medtronic, Inc., which over the number of 2000. CDHT has already built up an initial formation of modern Chinese medicine, chemical drugs, biological agents, medical devices and other key industrial clusters, more than 50,000 employees. The total construction area is 560,000 square meters, including Tianfu Life Science and Technology Park Phase I and Tianfu Life Science and Technology Park Phase II (Xinchuan Biopharmaceutical Innovation Incubator Park), Tianhe hatching Park 3 biological industry professional parks.

INTRODUCTION OF BIO-TOWN

With an area about 44 square kilometers, Chengdu Tianfu International Bio-town was designed and constructed under requirements and ideas of various functional industry zones. Aiming at establishing an international top-class bioindustrial zone which is competitive around the world and driving the modern bioindustry in this southwestern part of China, this Bio-town would be a world famous habitat of bioindustry innovative and entrepreneurial talents, world-class capital of innovation and smart manufacture industry, and internationalized town of life and health.

Innovative practice area integrated in the high end of global industrial chain and core of value chain is to support the four dimensional development; taking the construction of “four chain, one community, one system” bio-industry ecosystem as the implementation path; talents gathering as the core leading factor of industrial development; focusing on the four major industries of biomedicine, biomedical engineering, biological services, and new economy of health; putting efforts in developing 6 specific services in this filed including biotechnology drugs, new medical drugs, modern Chinese medicine, high-performance medical equipment, smart health plus precision medicine and professional outsourcing services; rapidly establishing five central functions which are the Global Bio-medicine Supply Chain Service Center, International Good Clinal Practice (GCP) Service Center for Drugs and Medical Devices, Global Outsourcing Production Center for Biotech Drugs.

Following the developing concept of combining production, life and ecology, Chengdu Tianfu International Bio-town was constructed according to the requirements of “Park City”, advocating the urban atmosphere of “knowledge plus art and health”, promoting low-carbon development and healthy lifestyle, creating a living international community that integrates charm, humanity, vitality, quality and characteristics, and establishing the homeland of Global Bio City named My BIO-TOWN.

Relying on the area of 0.27 square kilometers of Yong'an Lake ecological green heart, Jinjiang high-quality water resources and lush vegetation, a bio-city central forest park would be placed. Circled by the forest and gardens, an urban greenway system would be built up around labs and the city, which connects the working and living space.

Two different neighbor centers would be established to play an important role in society and production in order to make an convenient 7/24 healthy lifestyle and an multifunctional social community with communication, entertainment and public services. As the National Major New Drug R&D Project Technology Transfer & Commercialization Pilot Base, the emonstrative zone of Running MAH and the functional industry demonstrative zone of Chengdu, Chengdu Tianfu International Bio-town has already attracted 113 projects and commercial investment which above 100 billion at present. There are 13 innovative medicine varieties, 27 first generic medicine varieties and 24 innovation platforms been attracted , including 4 Nobel Prize teams, 3 academicians groups of the Academy of Science and the Academy of Engineering and 32 groups of high-level oversea talents.

Moreover, the first batch of medical products from the Allergan Biologics Ltd. were cleared in Chengdu on the 15th of April in 2019. This is the first time that an international company has chosen to implement customs clearance through both routes of the air and the rail in Chengdu. It marks the official establishment of the global biomedical supply chain service center in Chengdu and has the ability to serve the world. As the premier carrier of the biomedical industry of Chengdu, Chengdu Tianfu International Bio-town is also expected to take another critical step towards the goal for serving the world.